Abstract
Over the past decade, vulnerability- and psychosis-associated structural and functional brain abnormalities in a population at high clinical risk to develop psychosis were intensively studied. We reviewed the results from studies comparing at-risk mental state (ARMS) individuals with and without subsequent transition to psychosis. Additionally, we introduced a new concept of splitting ARMS population according to the duration of the psychosis risk syndrome and their probability to develop psychosis. Studying the ARMS individuals still vulnerable to psychosis but with lower risk to transit can disclose the possible protective – resilience factors or characteristics. Resilience, understood as ability to recover from change, can be thus applied in the early intervention for high clinical risk for psychosis individuals.
Keywords: At-risk mental state (ARMS), transition, psychosis, resilience, magnetic resonance imaging (MRI), gray matter, abnormal experiences, temporal gyrus, insular volume, clinical psychiatry
Current Pharmaceutical Design
Title: Neuroimaging and Resilience Factors - Staging of the At-risk Mental State?
Volume: 18 Issue: 4
Author(s): Renata Smieskova, Paolo Fusar-Poli, Anita Riecher-Rossler and Stefan Borgwardt
Affiliation:
Keywords: At-risk mental state (ARMS), transition, psychosis, resilience, magnetic resonance imaging (MRI), gray matter, abnormal experiences, temporal gyrus, insular volume, clinical psychiatry
Abstract: Over the past decade, vulnerability- and psychosis-associated structural and functional brain abnormalities in a population at high clinical risk to develop psychosis were intensively studied. We reviewed the results from studies comparing at-risk mental state (ARMS) individuals with and without subsequent transition to psychosis. Additionally, we introduced a new concept of splitting ARMS population according to the duration of the psychosis risk syndrome and their probability to develop psychosis. Studying the ARMS individuals still vulnerable to psychosis but with lower risk to transit can disclose the possible protective – resilience factors or characteristics. Resilience, understood as ability to recover from change, can be thus applied in the early intervention for high clinical risk for psychosis individuals.
Export Options
About this article
Cite this article as:
Smieskova Renata, Fusar-Poli Paolo, Riecher-Rossler Anita and Borgwardt Stefan, Neuroimaging and Resilience Factors - Staging of the At-risk Mental State?, Current Pharmaceutical Design 2012; 18 (4) . https://dx.doi.org/10.2174/138161212799316046
DOI https://dx.doi.org/10.2174/138161212799316046 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cognitive Dysfunction in Major Depressive Disorder: A State-of-the-Art Clinical Review
CNS & Neurological Disorders - Drug Targets Statistical Voxel-Based Methods and [18F]FDG PET Brain Imaging: Frontiers for the Diagnosis of AD
Current Alzheimer Research Artery of Percheron Infarction: A Characteristic Pattern of Ischemia and Variable Clinical Presentation: A Literature Review
Current Medical Imaging Opiate Drug Use and the Pathophysiology of NeuroAIDS
Current HIV Research Amyotrophic Lateral Sclerosis Treatment with Ultramicronized Palmitoylethanolamide: A Case Report
CNS & Neurological Disorders - Drug Targets Pharmacological Approaches to Induce Neuroregeneration in Spinal Cord Injury: An Overview
Current Drug Discovery Technologies A Study of Extrapyramidal Manifestations Accompanying Decompensated Viral Hepatic Cirrhosis Patients
Reviews on Recent Clinical Trials Selegiline (l-Deprenyl) as a Unique Neuroprotective Agent for Chronic Neurodegenerative Disorders- A Lesson from MAO Inhibition
Current Medicinal Chemistry - Central Nervous System Agents Animal Models Used for the Evaluation of Antiretroviral Therapies
Current HIV Research Control of Neuropathic Pain by Immune Cells and Opioids
CNS & Neurological Disorders - Drug Targets Future Perspectives on the Fibrinolytic Therapy of Intracerebral Hemorrhages
Central Nervous System Agents in Medicinal Chemistry Myofascial Temporomandibular Disorder
Current Rheumatology Reviews The Role of the PACAP Signaling System in Depression
Current Pharmaceutical Design Neuroimaging of Cancer Patients for Psychosocial Support and Patient Care
Current Medical Imaging Editorial [Hot topic:Pharmacological Brain Imaging in the Healthy and Sick Brain (Executive Editor: F.M. Van Der Veen)]
Current Pharmaceutical Design Human Model Neurons in Studies of Brain Cell Damage and Neural Repair
Current Molecular Medicine Central Nervous System Vasculitis: Still More Questions than Answers
Current Neuropharmacology Functions of Fukutin, a Gene Responsible for Fukuyama Type Congenital Muscular Dystrophy, in Neuromuscular System and Other Somatic Organs
Central Nervous System Agents in Medicinal Chemistry Nose to Brain Delivery of Nanoformulations for Neurotherapeutics in Parkinson’s Disease: Defining the Preclinical, Clinical and Toxicity Issues
Current Drug Delivery Role of Pituitary Adenylate Cyclase-Activating Polypeptide in Nociception and Migraine
CNS & Neurological Disorders - Drug Targets